# Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

> **NCT04512716** · EARLY_PHASE1 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 12 (estimated)

## Conditions studied

- B-ALL
- DLBCL
- B ALL
- Dlbcl-Ci
- DLBCL Unclassifiable
- DLBCL, Nos Genetic Subtypes
- DLBCL Activated B-Cell Type
- DLBCL Germinal Center B-Cell Type
- Diffuse Large B-cell Lymphoma
- HGBL
- HGBL, Nos

## Interventions

- **DRUG:** 131-I Apamistamab
- **BIOLOGICAL:** CAR T-cell

## Key facts

- **NCT ID:** NCT04512716
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-02-02
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04512716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04512716, "Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-07-21 from https://api.ai-analytics.org/clinical/NCT04512716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*